Transcription factors are proteins that bind specifically to defined DNA sequences to promote gene expression. Targeting transcription factors with small molecules to modulate the expression of certain genes has been notoriously difficult to achieve. The natural product thiostrepton is known to reduce the transcriptional activity of FOXM1, a transcription factor involved in tumorigenesis and cancer progression. Herein we demonstrate that thiostrepton interacts directly with FOXM1 protein in the human breast cancer cells MCF-7. Biophysical analyses of the thiostrepton–FOXM1 interaction provide additional insights on the molecular mode of action of thiostrepton. In cellular experiments, we show that thiostrepton can inhibit the binding of FOXM1 to genomic target sites. These findings illustrate the potential druggability of transcription factors and provide a molecular basis for targeting the FOXM1 family with small molecules.
Subscribe to Journal
Get full journal access for 1 year
only $13.33 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schreiber, S. L. The small-molecule approach to biology. Chem. Eng. News 81, 51–61 (2003).
Stockwell, B. R. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1, 116–125 (2000).
Altmann, K-H. et al. The state of the art of chemical biology. ChemBioChem 10, 16–29 (2009).
Tan, D. S. Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat. Chem. Biol. 1, 74–84 (2005).
Berg, T. Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 12, 464–471 (2008).
Arndt, H-D. Small molecule modulators of transcription. Angew. Chem. Int. Ed. 45, 4552–4560 (2006).
Gottesfeld, J. M., Neely, L., Trauger, J. W., Baird, E. E. & Dervan, P. B. Regulation of gene expression by small molecules. Nature 387, 202–205 (1997).
Kung, A. L. et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 6, 33–43 (2004).
Ng, P. Y., Tang, Y., Knosp, W. M., Stadler, H. S. & Shaw, J. T. Synthesis of diverse lactam carboxamides leading to the discovery of a new transcription-factor inhibitor. Angew. Chem. Int. Ed. 46, 5352–5355 (2007).
Verdine, G. L. & Walensky, L. D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264–7270 (2007).
Bauer, R. A., Wurst, J. M. & Tan, D. S. Expanding the range of ‘druggable’ targets with natural product-based libraries: an academic perspective. Curr. Opin. Chem. Biol. 14, 308–314 (2010).
Koehler, A. N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331–340 (2010).
Lai, E. et al. HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes Dev. 4, 1427–1436 (1990).
Weigel, D., Jürgens, G., Küttner, F., Seifert, E. & Jäckle, H. The homeotic gene forkhead encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 57, 645–658 (1989).
Krupczak-Hollis, K. et al. The mouse forkhead box m1 transcription factor is essential for hepatoblast mitosis and development of intrahepatic bile ducts and vessels during liver morphogenesis. Dev. Biol. 276, 74–88 (2004).
Kalin, T. V. et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712–1720 (2006).
Myatt, S. S. & Lam, E. W-F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 7, 847–859 (2007).
Pagano, J. F., Weinstein, M. J., Stout, H. A. & Donovick, R. Thiostrepton, a new antibiotic. I. In vitro studies. Antibiot. Ann. 554–559 (1955/1956).
Vendeputte, J. & Dutcher, J. D. Thiostrepton, a new antibiotic. II. Isolation and chemical characterization. Antibiot. Ann. 560–561 (1955/1956).
Steinberg, B. A., Jambor, W. P. & Suydam, L. O. Thiostrepton, a new antibiotic. III. In vivo studies. Antibiot. Ann. 562–565 (1955/1956).
Bagley, M. C., Dale, J. W., Merritt, E. A. & Xiong, X. Thiopeptide antibiotics. Chem. Rev. 105, 685–714 (2005).
Bhat, U. G., Zipfel, P. A., Tyler, D. S. & Gartel, A. L. Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle 7, 1851–1855 (2008).
Bowling, B. D., Doudican, N., Manga, P. & Orlow, S. J. Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother. Pharmacol. 63, 37–43 (2008).
Nicolaou, K. C. et al. Discovery of a biologically active thiostrepton fragment. J. Am. Chem. Soc. 127, 15042–15044 (2005).
Kwok, J. M. et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther. 7, 2022–2032 (2008).
Bhat, U. G., Halasi, M. & Gartel, A. L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PloS One 4, e5592 (2009).
Bhat, U. G., Halasi, M. & Gartel, A. L. FoxM1 is a general target for proteasome inhibitors. PloS One 4, e6593 (2009).
Schoof, S. et al. Antiplasmodial thiostrepton derivatives: proteasome inhibitors with a dual mode of action. Angew. Chem. Int. Ed. 49, 3317–3321 (2010).
Zhang, L. et al. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 579, 6423–6427 (2005).
Halasi, M. & Gartel, A. L. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8, 1966–1967 (2009).
Leslie, B. J. & Hergenrother, P. J. Identification of the cellular targets of bioactive small organic molecules using affinity reagents. Chem. Soc. Rev. 37, 1347–1360 (2008).
Anderson, B., Hodgkin, D. C. & Viswamitra, M. A. The structure of thiostrepton. Nature 225, 233–235 (1970).
Schoof, S., Baumann, S., Ellinger, B. & Arndt, H-D. A fluorescent probe for the 70 S-ribosomal GTPase-associated center. ChemBiochem 10, 242–245 (2009).
Wierstral, I. & Alves, J. Despite its strong transactivation domain, transcription factor FOXM1c is kept almost inactive by two different inhibitory domains. Biol. Chem. 387, 963–976 (2006).
Yao, K. M., Sha, M., Lu, Z. & Wong, G. G. Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J. Biol. Chem. 272, 19827–19836 (1997).
Block, K. M. et al. Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J. Am. Chem. Soc. 131, 18078–18088 (2009).
Wierstra, I. & Alves, J. Cyclin E/Cdk2, P/CAF, and E1A regulate the transactivation of the c-myc promoter by FOXM1. Biochem. Biophys. Res. Commun. 368, 107–115 (2008).
Wang, I-C. et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 25, 10875–10894 (2005).
Leung, T. W. C. et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 507, 59–66 (2001).
Doisneau-Sixou, S. F. et al. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10, 179–186 (2003).
Rae, J. M. et al. GREB1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res. Treat. 92, 141–149 (2005).
Gomez, B. P. et al. Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 21, 4013–4027 (2007).
Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27–33 (2011).
Schmidt, D. et al. ChIP-seq: using high-throughput sequencing to discover protein–DNA interactions. Methods 48, 240–248 (2009).
Gemenetzidis, E. et al. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res. 70, 9515–9526 (2010).
We thank R. Kranaster, P. Sledz and C. Ross-Innes for discussions and advice and C. D'Santos for mass spectrometry analysis and C. Lowe for proof-reading the manuscript. We thank the Cambridge Commonwealth Trust and Trinity College, Cambridge, for a studentship (N.H.) and the Biotechnology and Biological Sciences Research Council for grant funding. S.B.'s laboratory is supported by programme funding from Cancer Research UK. R.R. is a Herchel Smith Research Fellow.
The authors declare no competing financial interests.
About this article
Cite this article
Hegde, N., Sanders, D., Rodriguez, R. et al. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nature Chem 3, 725–731 (2011) doi:10.1038/nchem.1114
A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactions
Bioorganic Chemistry (2019)
Ala-geninthiocin, a new broad spectrum thiopeptide antibiotic, produced by a marine Streptomyces sp. ICN19
The Journal of Antibiotics (2019)
Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer
Molecular Oncology (2019)
Scientific Reports (2019)
Selective Modification of Ribosomally Synthesized and Post‐Translationally Modified Peptides (RiPPs) through Diels–Alder Cycloadditions on Dehydroalanine Residues
Chemistry – A European Journal (2019)